These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33152758)

  • 1. Remdesivir and GS-441524 plasma concentrations in patients with end-stage renal disease on haemodialysis.
    Davis MR; Pham CU; Cies JJ
    J Antimicrob Chemother; 2021 Feb; 76(3):822-825. PubMed ID: 33152758
    [No Abstract]   [Full Text] [Related]  

  • 2. Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity.
    Yan VC; Muller FL
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32988821
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of OATP4C1 in Renal Handling of Remdesivir and its Nucleoside Analog GS-441524: The First Approved Drug for Patients with COVID-19.
    Sato T; Maekawa M; Mano N; Abe T; Yamaguchi H
    J Pharm Pharm Sci; 2021; 24():227-236. PubMed ID: 34048668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reply to Yan and Muller, "Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity".
    Lê MP; Le Beller C; Le Hingrat Q; Jaquet P; Wicky PH; Bunel V; Massias L; Visseaux B; Messika J; Descamps D; Mal H; Timsit JF; Peytavin G
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32988815
    [No Abstract]   [Full Text] [Related]  

  • 5. Quantification of plasma remdesivir and its metabolite GS-441524 using liquid chromatography coupled to tandem mass spectrometry. Application to a Covid-19 treated patient.
    Alvarez JC; Moine P; Etting I; Annane D; Larabi IA
    Clin Chem Lab Med; 2020 Aug; 58(9):1461-1468. PubMed ID: 32573468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis.
    Sörgel F; Malin JJ; Hagmann H; Kinzig M; Bilal M; Eichenauer DA; Scherf-Clavel O; Simonis A; El Tabei L; Fuhr U; Rybniker J
    J Antimicrob Chemother; 2021 Feb; 76(3):825-827. PubMed ID: 33251541
    [No Abstract]   [Full Text] [Related]  

  • 7. Hemoadsorption eliminates remdesivir from the circulation: Implications for the treatment of COVID-19.
    Biever P; Staudacher DL; Sommer MJ; Triebel H; Neukamm MA; Bode C; Supady A; Lother A
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00743. PubMed ID: 33710753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remdesivir use in COVID-19 patients with end-stage kidney disease on intermittent hemodialysis: An absolute contraindication?
    Haddad I; Agarwal P; Hassanein M
    Ther Apher Dial; 2022 Aug; 26(4):850-851. PubMed ID: 35261170
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative bioavailability study following a single dose intravenous and buccal administration of remdesivir in rabbits.
    Szente L; Renkecz T; Sirok D; Stáhl J; Hirka G; Puskás I; Sohajda T; Fenyvesi É
    Int J Pharm; 2022 May; 620():121739. PubMed ID: 35421532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients.
    Leegwater E; Moes DJAR; Bosma LBE; Ottens TH; van der Meer IM; van Nieuwkoop C; Wilms EB
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0025422. PubMed ID: 35647646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of GS-441524, the active metabolite of remdesivir, in patients receiving continuous renal replacement therapy: A case series.
    Nishikawa A; Ito I; Yonezawa A; Itohara K; Matsubara T; Sato Y; Matsumura K; Hamada S; Tanabe N; Kai S; Imoto E; Yoshikawa K; Ohtsuru S; Yanagita M; Hirai T; Terada T
    J Infect Chemother; 2024 Apr; 30(4):348-351. PubMed ID: 37866621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19.
    Adamsick ML; Gandhi RG; Bidell MR; Elshaboury RH; Bhattacharyya RP; Kim AY; Nigwekar S; Rhee EP; Sise ME
    J Am Soc Nephrol; 2020 Jul; 31(7):1384-1386. PubMed ID: 32513665
    [No Abstract]   [Full Text] [Related]  

  • 13. Plasma concentrations of alpha-melanocyte-stimulating hormone are elevated in patients on chronic haemodialysis.
    Airaghi L; Garofalo L; Cutuli MG; Delgado R; Carlin A; Demitri MT; Badalamenti S; Graziani G; Lipton JM; Catania A
    Nephrol Dial Transplant; 2000 Aug; 15(8):1212-6. PubMed ID: 10910447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
    Josephs D; Hutson TE; Cowey CL; Pickering LM; Larkin JM; Gore ME; Van Hemelrijck M; McDermott DF; Powles T; Chowdhury P; Karapetis C; Harper PG; Choueiri TK; Chowdhury S
    BJU Int; 2011 Oct; 108(8):1279-83. PubMed ID: 21244613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenine nucleotide concentrations and energy charge in muscle of chronic haemodialysis patients.
    Cleminson WG; Manchester KL; Diesel WJ; Margolius LP
    Nephron; 1992; 60(2):232-4. PubMed ID: 1309168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remdesivir Use in COVID-19 Patients: Cutaneous Adverse Effect or Disease Manifestation?
    Pulsipher KJ; Presley CL; Szeto MD; Waller JD; Dellavalle RP
    J Drugs Dermatol; 2021 May; 20(5):575. PubMed ID: 33938699
    [No Abstract]   [Full Text] [Related]  

  • 17. [Remdesivir for patients with severe COVID-19].
    Augustin M; Hallek M; Nitschmann S
    Internist (Berl); 2020 Jun; 61(6):644-645. PubMed ID: 32333086
    [No Abstract]   [Full Text] [Related]  

  • 18. Response of serum angiotensin converting enzyme, plasma renin activity and plasma aldosterone to conventional dialysis in patients on chronic haemodialysis.
    Letizia C; Mazzaferro S; Morabito S; De Ciocchis A; Cerci S; D'Ambrosio C; Cinotti GA; Scavo D
    Int Urol Nephrol; 1995; 27(4):465-70. PubMed ID: 8586522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous N-acetylcysteine during haemodialysis reduces the plasma concentration of homocysteine in patients with end-stage renal disease.
    Thaha M; Yogiantoro M; Tomino Y
    Clin Drug Investig; 2006; 26(4):195-202. PubMed ID: 17163251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
    de Wit E; Feldmann F; Cronin J; Jordan R; Okumura A; Thomas T; Scott D; Cihlar T; Feldmann H
    Proc Natl Acad Sci U S A; 2020 Mar; 117(12):6771-6776. PubMed ID: 32054787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.